The Compliance Side of Selling Peptides in a Wellness Practice

Of all the reasons a wellness practice hesitates before adding peptides, compliance is usually the loudest. The category sits in a genuinely unsettled part of the regulatory map, the rules have been moving, and the consequences of getting it wrong land on the practice rather than the manufacturer. That uncertainty is real, but it is not a reason to avoid the conversation. It is a reason to have a clear, defensible posture before the first patient asks. This article lays out the compliance terrain as it stands and the framework that keeps a peptide program accurate and protected. It is written for providers and is not legal advice; rules vary by state, by product, and by the moment, so confirm specifics with your own counsel and licensing board.

Why "Peptide" Does Not Mean "Approved"

The first compliance trap is linguistic. Patients and providers alike hear "peptide" and assume a single regulatory status, when in fact the word covers several. Peptides are a legitimate and well-established drug class: more than 80 peptide drugs have reached the market since insulin, treating conditions from diabetes to osteoporosis to chronic pain.¹ Insulin, semaglutide, and tirzepatide are peptides, and they are FDA-approved drugs that went through full clinical review.

The peptides circulating in the wellness space are a different population. Most are neither FDA-approved drugs nor legal dietary supplements. The Food and Drug Administration limits dietary supplements largely to vitamins, minerals, herbs, amino acids, and similar substances, and it does not review supplements for safety and effectiveness the way it reviews drugs before they reach the market.⁵ Many wellness peptides fall outside the supplement definition and have not been approved as drugs either, which leaves them in a gray area rather than a green one. The compliant provider treats that distinction as the starting point of every conversation: this is a peptide, and it is not an FDA-approved treatment for anything.

The Compounding Pathway Is Tightening

Some peptides reach patients through compounding pharmacies rather than as finished manufactured products, and that route is under active and shifting FDA review. Compounding under Section 503A relies on lists of bulk drug substances the agency has evaluated. The FDA finalized its interim policy on compounding with bulk substances in early 2025, and the practical effect is restrictive: a substance that is not on the agency's final approved bulks list generally may not be compounded until the FDA completes its review and chooses to add it.² The category status of individual peptides has changed more than once, and the advisory committee continues to take them up, so any provider relying on a compounded peptide should verify its current standing rather than assume last year's answer still holds.

Manufactured oral dissolving strips are a different supply format from compounded injectables, but the same first question applies to both: what is the regulatory status of this product, and what can be said truthfully about it? A clean supply chain and a manufacturer that can document its process matter regardless of format. The format does not convert a non-approved peptide into an approved drug, and no responsible program should imply that it does.

The Claims Line Is the One Most Practices Cross

The single most common compliance failure in peptide marketing is not sourcing. It is the claim. The Federal Trade Commission rewrote its guidance on health advertising in December 2022, and the updated Health Products Compliance Guidance applies to advertising for all health-related products, not only dietary supplements.³ Its core requirement is a high bar: a health-related claim must be supported by competent and reliable scientific evidence, which the FTC describes as generally consisting of randomized, controlled human clinical trials conducted by qualified experts. The guidance is explicit that animal studies, in vitro studies, and surveys of consumer experiences cannot, standing alone, substantiate a health claim.³

That standard collides directly with how peptides are usually marketed. The evidence base for many popular wellness peptides is preclinical. A widely cited review of BPC-157 in musculoskeletal soft tissue healing concluded that the studies were performed largely in small rodent models and that its efficacy is yet to be confirmed in humans.⁴ Under the FTC standard, that body of evidence cannot support a benefit claim to patients, full stop. Pairing it with a testimonial does not help, because testimonials cannot substantiate a claim either. The compliant move is to describe mechanism and the state of the research honestly, label preclinical findings as preclinical, and never promise an outcome. Our piece on talking to patients about peptides without overclaiming works through the exact language that keeps these conversations on the right side of the line.

One more point that practices miss: the claims rule covers the whole footprint, not just the official brochure. Website copy, social posts, intake scripts, what front-desk staff say, and what a provider says verbally in the room are all advertising in the eyes of a regulator. Disease claims, the implication that a product can diagnose, treat, cure, or prevent a condition, are the brightest line of all, and they can convert a wellness product into an unapproved drug claim in a single sentence.

Scope of Practice and the Medical Director Question

Compliance is not only federal. Who may recommend, sell, or administer a given peptide depends heavily on state law and on the practitioner's license. The rules that govern an injectable program, with its prescribing and oversight requirements, are not the same as the rules around an oral, non-injectable product, and they differ again from state to state. A provider adding peptides needs to know which products their license actually permits them to offer, and whether a medical director or supervising physician is required for the specific format and route they intend to use. We covered the practical version of this question in our article on adding a peptide program without a medical director, and it remains the right place to start that analysis.

The Anti-Doping Line Providers Forget

One compliance category gets missed almost universally because it does not feel like compliance: competitive athletes. Many of the peptides discussed in wellness settings, including growth hormone secretagogues and the GH-releasing peptides, appear on the World Anti-Doping Agency Prohibited List and are banned both in and out of competition.⁶ A product that is unremarkable for a general wellness patient can end the eligibility of a patient who competes at any sanctioned level. Screening for competitive status belongs in intake, and the same discipline applies when patients ask about combining agents, a topic we address in our piece on stacking peptides safely.

Documentation Is the Cheapest Insurance

The thread running through every section above is the record. The conversation, the rationale, the disclosure that the product is not FDA-approved, the patient's understanding that no outcome is guaranteed, and any screening for contraindications or competitive status all belong in the chart. None of it is expensive, and all of it is what a defensible program looks like in hindsight. When a question arises later, a practice with documentation has a story; a practice without it has a problem. Restraint and record-keeping are not the parts of a peptide program that generate revenue, but they are the parts that let the revenue continue.

The Bottom Line for Practices

The compliance side of selling peptides looks intimidating because it is unsettled, but the operating rules are surprisingly stable. Know that a peptide is not automatically an approved drug. Verify the regulatory status and the sourcing of every product you carry. Hold your claims to the competent-and-reliable-evidence standard and avoid disease claims entirely. Stay inside your license and your state's rules. Screen for athletes. Document everything. None of that requires a law degree, and all of it happens to be the same posture that earns trust from a skeptical, regulation-sensitive audience. In this category, the conservative practice is also the credible one, and credibility is what keeps providers in the program for the long run.

The oral dissolving strips in our wholesale program use patented InstaRelease® technology by InstaMed, and our team can walk you through product documentation and sourcing before you decide. Apply for a free wholesale account.

References

1. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. PubMed: 33536635
2. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov
3. Federal Trade Commission. Health Products Compliance Guidance. December 2022. FTC.gov
4. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PubMed: 30915550
5. U.S. Food and Drug Administration. Dietary Supplements. FDA.gov
6. World Anti-Doping Agency. The Prohibited List. WADA

Disclaimer: This article is for educational purposes for healthcare providers and is not medical, legal, or regulatory advice. Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease, and they are not FDA-approved. Regulations governing peptides vary by jurisdiction and change over time; providers are responsible for confirming the current legal status of any product and for evaluating clinical use within their own scope of practice and applicable laws.